Genzyme offers to buy research and development (R&D) unit for stock
This article was originally published in Clinica
Genzyme intends to acquire Genzyme Development Partners, also known as the Surgical Aids Partnership, for around $93 million in Genzyme General Division shares. Genzyme established the Surgical Aids Partnership in 1989, raising $37 million to fund the development of surgical products to reduce post-operative adhesions. If Genzyme did not exercise its option to purchase Surgical Aids Partnership, it would only have limited rights in revenues generated from the four products based on hyaluronic acid which are in development.
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.